COVID-19. Clinically-epidemiologically diagnosed COVID-19
Conditions
Interventions
Intervention 1: Intervention group: Prescribing 6 mg of melatonin capsules made by Elite factory for 2 weeks, which should be consumed half an hour before bedtime every night in low light conditions a
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
25 Years to 65 Years
Inclusion criteria
Inclusion criteria: mild to moderate patients with COVID-19 who receive Hydroxy chloroquine Confirmation of the disease is based on CT scan and clinical symptoms and physician diagnosis Patients 25-65 years
Exclusion criteria
Exclusion criteria: Patient with depression, COPD, sleep apnea and seizure Patients with severe kidney problem (eGFR<30 ml/min) Patients with severe liver problem Patients who receive fluvoxamine, benzodiazepine or zolpidem patients who receive drugs that extends QT Pregnant and breastfeeding mothers Patients who have allergy to melatonin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Headache. Timepoint: 10-14 days. Method of measurement: COVID-19 questionnaire.;Lung infection. Timepoint: 10-14 days. Method of measurement: CTscan and physician diagnosis.;CRP ( C reactive protein). Timepoint: 10-14 days. Method of measurement: Lab test.;Fever. Timepoint: 10-14days. Method of measurement: questionnaire.;Vomiting. Timepoint: 10-14 days. Method of measurement: Questionnaire.;No smelling. Timepoint: 10-14 days. Method of measurement: questionnaire.;No taste. Timepoint: 10-14 days. Method of measurement: questionnaire.;Cough. Timepoint: 10-14 days. Method of measurement: Questionnaire.;Respiratory distress. Timepoint: 10-14days. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Alizadeh
Immunology, Asthma & Allergy Research Institute
Outcome results
None listed